The Role of Inflammatory Cytokines (Interleukin-1 and Interleukin-6) as a Potential Biomarker in the Different Stages of COVID-19 (Mild, Severe, and Critical)

被引:13
作者
Nezhad, Mina Ghofrani [1 ]
Jami, Giti [1 ]
Kooshkaki, Omid [1 ]
Chamani, Sajjad [1 ]
Naghizadeh, Ali [1 ]
机构
[1] Birjand Univ Med Sci BUMS, Med Toxicol & Drug Abuse Res Ctr MTDRC, Birjand 9717844741, Iran
关键词
COVID-19; SARS-CoV-2; IL-6; IL-1; CRP cytokine storm; tocilizumab; anakinra; MACROPHAGE ACTIVATION SYNDROME; RECEPTOR ANTAGONIST ANAKINRA; C-REACTIVE PROTEIN; TNF-ALPHA; STORM; CORONAVIRUS; IL-6; EFFICACY; BLOCKADE; SAFETY;
D O I
10.1089/jir.2022.0185
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cytokine storm refers to the overproduction of immune and inflammatory cells and their proteins (cytokines) [interleukin (IL)-1 and IL-6] causing acute respiratory distress syndrome in COVID-19. COVID-19 causes inflammatory reactions, and patients with COVID-19 had categorized as mild, severe, and critical after reviewing previous studies. Then, it is crucial to find immune-inflammatory indicators that might predict the disorder severity and the prognosis primarily for guiding medical therapy in the face of this unexpectedly developing unique infectious disease. Higher levels of IL-6 and IL-1 levels might be seen in patients with COVID-19 at each stage. In addition, IL-1-induced IL-6 assists in the synthesis of liver C-reactive protein (CRP) in acute phase responses. Recent studies suggested that IL-6 levels are an independent predictor of COVID-19 illness because they were significantly higher in patients with severe than with mild COVID-19 symptoms. Anakinra and tocilizumab (TCZ) are beneficial in lowing mortality in COVID-19 patients; however, information on their safety and efficacy is scarce. The aim of this study was to investigate the role of inflammatory cytokines (IL-1 and IL-6) as potential biomarkers in the different stages (mild, severe, and critical) of COVID-19. A systematic search during the years 2021-2022 using the keywords SARS-CoV-2, COVID-19, IL-6, IL-1, CRP, mild stage, severe stage, critical stage, cytokine storm, tocilizumab, and anakinra was performed in PubMed and Google Scholar databases. This study reviews studies that have investigated the role of high levels of these cytokines in the severity of the disease in patients with COVID-19 and the inhibitory function of TCZ and anakinra in preventing mechanical ventilation and patient mortality. According to the result, studies suggest that decreased innate immune response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in association with the production of inflammatory cytokines is the determining and driving function of COVID-19.
引用
收藏
页码:147 / 163
页数:17
相关论文
共 182 条
  • [1] COVID-19 and the Heart
    Akhmerov, Akbarshakh
    Marban, Eduardo
    [J]. CIRCULATION RESEARCH, 2020, 126 (10) : 1443 - 1455
  • [2] Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review
    Alijotas-Reig, Jaume
    Esteve-Valverde, Enrique
    Belizna, Cristina
    Selva-O'Callaghan, Albert
    Pardos-Gea, Josep
    Quintana, Angela
    Mekinian, Arsene
    Anunciacion-Llunell, Ariadna
    Miro-Mur, Francesc
    [J]. AUTOIMMUNITY REVIEWS, 2020, 19 (07)
  • [3] A review of potential treatments to date in COVID-19 patients according to the stage of the disease
    Alsuliman, Tamim
    Alasadi, Lugien
    Alkharat, Banan
    Srour, Micha
    Alrstom, Ali
    [J]. CURRENT RESEARCH IN TRANSLATIONAL MEDICINE, 2020, 68 (03) : 93 - 104
  • [4] Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series
    Aouba, Achille
    Baldolli, Aurelie
    Geffray, Loik
    Verdon, Renaud
    Bergot, Emmanuel
    Martin-Silva, Nicolas
    Justet, Aurelien
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (10) : 1381 - 1381
  • [5] Interleukin-1 Inhibitors and Vaccination Including COVID-19 in Inflammatory Rheumatic Diseases: A Nonsystematic Review
    Ataguenduez, Pamir
    Keser, Goekhan
    Soy, Mehmet
    [J]. FRONTIERS IN IMMUNOLOGY, 2022, 12
  • [6] Elevated interleukin-6 and severe COVID-19: A meta-analysis
    Aziz, Muhammad
    Fatima, Rawish
    Assaly, Ragheb
    [J]. JOURNAL OF MEDICAL VIROLOGY, 2020, 92 (11) : 2283 - 2285
  • [7] Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms
    Baig, Abdul Mannan
    Khaleeq, Areeba
    Ali, Usman
    Syeda, Hira
    [J]. ACS CHEMICAL NEUROSCIENCE, 2020, 11 (07): : 995 - 998
  • [8] Symptoms and laboratory manifestations of mild COVID-19 in a repatriated cruise ship cohort
    Bailie, C. R.
    Franklin, L.
    Nicholson, S.
    Mordant, F.
    Alpren, C.
    Stewart, T.
    Barnes, C.
    Fox, A.
    Druce, J.
    Subbarao, K.
    Catton, M.
    van Diemen, A.
    Sullivan, S. G.
    [J]. EPIDEMIOLOGY AND INFECTION, 2021, 149
  • [9] COVID-19: Specific and Non-Specific Clinical Manifestations and Symptoms: The Current State of Knowledge
    Baj, Jacek
    Karakula-Juchnowicz, Hanna
    Teresinski, Grzegorz
    Buszewicz, Grzegorz
    Ciesielka, Marzanna
    Sitarz, Ryszard
    Forma, Alicja
    Karakula, Kaja
    Flieger, Wojciech
    Portincasa, Piero
    Maciejewski, Ryszard
    [J]. JOURNAL OF CLINICAL MEDICINE, 2020, 9 (06) : 1 - 22
  • [10] Cytokine Storm Syndrome: Looking Toward the Precision Medicine Era
    Behrens, Edward M.
    Koretzky, Gary A.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2017, 69 (06) : 1135 - 1143